Surbhi Sidana, MD, provides clinical insights on treatment sequencing strategies for patients with relapsed/refractory multiple myeloma.
FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma
SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM
Results from the phase 3 GMMG HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma
Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.
ODAC Votes Against 2 Belantamab Mafodotin Combinations in Multiple Myeloma
ODAC voted against the favorability of the agent in combination with dexamethasone and pomalidomide or bortezomib in multiple myeloma.